Email this article ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: THE PROBLEM OF EFFICIENCY, SAFETY AND COMPLIANCE
- Authors: Martsevich S.Y.1, Kutishenko N.P.2, Ginzburg M.L.3, Malysheva A.M.2, Polyanskaya Y.N.2
-
Affiliations:
- State Research Center for Preventive Medicine, Ministry of Health and Social Development of Russia I.M. Sechenov First Moscow State Medical University
- State Research Center for Preventive Medicine, Ministry of Health and Social Development of Russia
- Lyubertsy District Hospital № 2, Moscow Region
- Issue: Vol 5, No 2 (2011)
- Pages: 72-79
- Section: PHARMACOTHERAPY
- Published: 15.04.2011
- URL: https://klinitsist.abvpress.ru/Klin/article/view/125
- DOI: https://doi.org/10.17650/1818-8338-2011-2-72-79
- ID: 125
Cite item
Full Text
Abstract
Evidence based medicine data on ability of antiplatelet, including dual antiplatelet, therapy to improve the life expectancy of patients with high risk of thrombotic complications, especially patients with acute myocardial infarction is presented in brief. The problem of choosing a drug and resistance was overcoming. Modern clinical guidelines on safe antiplatelet therapy are presented.
About the authors
S. Yu. Martsevich
State Research Center for Preventive Medicine, Ministry of Health and Social Development of RussiaI.M. Sechenov First Moscow State Medical University
Author for correspondence.
Email: smartsevich@gnicpm.ru
Кафедра доказательной медицины Russian Federation
N. P. Kutishenko
State Research Center for Preventive Medicine, Ministry of Health and Social Development of RussiaRussian Federation
M. L. Ginzburg
Lyubertsy District Hospital № 2, Moscow RegionRussian Federation
A. M. Malysheva
State Research Center for Preventive Medicine, Ministry of Health and Social Development of RussiaRussian Federation
Yu. N. Polyanskaya
State Research Center for Preventive Medicine, Ministry of Health and Social Development of RussiaRussian Federation
References
Supplementary files
